5/25/2010

Abbott Laboratories will receive $30 million in milestone dues from Biogen Idec in connection with a Phase III trial for multiple sclerosis drug daclizumab. The companies will continue testing the experimental treatment in comparison with Biogen's FDA-approved Avonex.

Related Summaries